February 8, 2018 / 1:11 PM / 10 months ago

BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20

Feb 8 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY

* Q4 NON-GAAP LOSS PER SHARE $1.20

* EXPECTS TO END 2018 WITH APPROXIMATELY $1.0 BILLION IN CASH

* REAFFIRMED GUIDANCE TO INITIATE A COMPREHENSIVE PHASE 3 PROGRAM FOR ALN-TTRSC02 IN LATE 2018

* QTRLY LOSS PER SHARE $1.48

* REVENUES WERE $37.9 MILLION IN Q4 OF 2017, AS COMPARED TO $17.5 MILLION IN Q4 OF 2016

* Q4 EARNINGS PER SHARE VIEW $-1.39 -- THOMSON REUTERS I/B/E/S

* EXPECTS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $400 MILLION TO $440 MILLION

* Q4 REVENUE VIEW $21.8 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below